<DOC>
	<DOCNO>NCT01344317</DOCNO>
	<brief_summary>Introduction : Methylxanthines doxapram widely use treatment apneas prematurity . Both substance effect central nervous system . While data available concern use caffeine ( methylxanthine use NICU ) even propose positive effect neurodevelopmental outcome preterm infant , data suggest negative effect central stimulant doxapram longterm outcome group infant . Nevertheless concern medication study publish scarce data available concern effect medication brain activity preterm infant . The aim study : assessment effect stimulate substance brain activity preterm infant bear 30 week gestation longterm neurodevelopmental follow-up . Methods : This study prospective study include preterm infant bear 30 week gestational age . Brain activity measure one-channel amplitude-integrated EEG ( aEEG ) . The first aEEG measurement perform without caffeine and/or doxapram medication . At least one hour brain activity registrated . The second measurement do least 24 hour start caffeine and/ doxapram treatment . The percentage different background pattern , occurrence duration sleep-wake-cycling , occurrence duration seizure assess analyse . Neurodevelopmental outcome assess one two year correct age assessment Bayley Scales Infant Development II standardize clinical neurological examination .</brief_summary>
	<brief_title>The Effect Stimulating Substances Brain Activity Preterm Infants</brief_title>
	<detailed_description />
	<mesh_term>Caffeine</mesh_term>
	<criteria>see intraventricular hemorrhage posthaemorrhagic hydrocephalus cerebral infection cerebral malformation</criteria>
	<gender>All</gender>
	<minimum_age>23 Weeks</minimum_age>
	<maximum_age>30 Weeks</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>